Figures
Abstract
Atopic dermatitis is a common, chronic and often debilitating inflammatory skin disorder with a large burden of its diagnosis and management falling within primary care. New advancements and updates to management are significantly improving the outcomes for patients with this condition.
Key Points
- Atopic dermatitis is a common condition and is largely managed in the primary care setting.
- Understanding and quantifying the impact of the condition on quality of life is important when tailoring therapy for patients.
- First-line therapy involves robust education around general measures and commencement of appropriate topical corticosteroid therapy.
- Should patients fail to respond to optimised general measures and topical corticosteroids after one month, they should be referred to a dermatologist.
- Dupilumab and upadacitinib are new advanced therapies that have profound benefits for patients with severe atopic dermatitis and have recently been added to the Pharmaceutical Benefits Scheme.
